Abstract

B-type natriuretic peptide (BNP) and amino-terminal pro-BNP (NT-proBNP) are promising cardiac biomarkers that have recently been shown to be of diagnostic value in decompensated heart failure, acute coronary syndromes and other conditions resulting in myocardial stretch and volume overload. In view of the high prevalence of cardiac disorders in the intensive care unit, the experience of elevated natriuretic peptide levels in the critically ill might be of enormous diagnostic and therapeutic value. BNP and NT-proBNP levels rise to different degrees in critical illness and may also serve as markers of severity and prognosis in diseases beyond acute or chronic heart failure. The diagnostic and prognostic use of natriuretic peptides in the intensive care setting for patients with various forms of shock could be an attractive alternative as noninvasive markers of cardiac dysfunction that could obviate the need for pulmonary artery catheterization in some patients.

In a recent issue of Critical Care, Januzzi and coworkers [1] report the results of a prospective cohort study, evaluating natriuretic peptides in various shock patients in the intensive care unit (ICU). The authors found no correlation between elevated levels of amino-terminal pro-BNP (NT-proBNP) and high filling pressures among patients with shock within the ICU, but higher values were reported to be strongly associated with death. A low level of NT-proBNP, however, identified low risk patients, who were less likely to benefit from pulmonary artery catheterization (PAC). The authors posed the question, therefore, whether NT-proBNP measurements can replace the need for PAC in ICU patients.

Brain natriuretic peptide (BNP) has been shown to be a useful cardiac biomarker for the identification of patients with suspected heart failure [2]. Elevated serum levels have been described in both left ventricular (LV) systolic and diastolic dysfunction as well as in right ventricular pressure overload states, such as pulmonary embolism, cor pulmonale and primary pulmonary hypertension [3]. BNP and its amino-terminal fragment NT-proBNP are markers of LV dysfunction, and elevated levels aid in discriminating cardiac from non-cardiac dyspnea [2]. Peptide levels also correlate with LV filling pressures (LVFP) in patients with depressed systolic function [4]. However, it is unclear whether BNP or NT-proBNP correlate with pulmonary capillary wedge pressure in a population of critically ill patients with a broad range of life-threatening diagnoses. Many critically ill patients have clinical and radiographic findings that cast doubt on LVFP. PAC has been used to measure LVFP and guide patient management. However, given its cost, complications, and evidence from recent studies that it has either a neutral or negative effect on ICU patient outcome, a reliable non-invasive method or parameter for the estimation of LVFP is needed [5,6].

Patients with various forms of shock have a high mortality in the ICU [7]. One method of evaluating patients with shock is invasive hemodynamic monitoring with PAC. In the modern era, however, non-invasive methods for estimating cardiac filling pressures and hemodynamics in ICU patients with shock, such as biomarkers capable of predicting prognosis, are coming to light. Several studies have shown that levels of the neurohormones BNP and NT-proBNP are increased in patients with cardiac dysfunction and severe sepsis or septic shock [8-12]. Moreover, these studies have shown that NT-proBNP can serve as an early marker of prognosis in this patient population [8,11].

Similar to previous examinations [13], Januzzi and coworkers [1] demonstrated that elevated levels of NT-proBNP were strongly associated with the risk of death in the ICU, and were even stronger predictors of death than APACHE II

BNP = brain natriuretic peptide; ICU = intensive care unit; IL = interleukin; LV = left ventricular; LVFP = left ventricular filling pressures; NT-proBNP = amino-terminal proBNP; PAC = pulmonary artery catheterization.
scores. It is doubtful, however, whether BNP or NT-proBNP correlate with invasively measured hemodynamic parameters, such as pulmonary capillary wedge pressure or low cardiac output in patients with various types of shock in the ICU [1,14]. In agreement with the findings reported by Jannuzzi and coworkers in the present issue of Critical Care [1], previous investigators reported that lower levels of NT-BNP identified patients with lower risk and better prognosis and that they may differentiate survivors from non-survivors in the ICU [8,11]. Thus, Jannuzzi and coworkers suggested that low NT-proBNP concentrations may be useful indicators to avoid PAC in low risk patients in the ICU.

Several mechanisms account for increased natriuretic peptide levels in shock patients and for the observed lack of association between natriuretic peptides and cardiac filling pressures and hemodynamics. First, lipopolysaccharide [15] and proinflammatory cytokines such as interleukin-1β [16] and cardiotrophin-1 [17] up-regulate transcription of the gene encoding BNP. Second, wall stretch can activate the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway in cardiomyocytes; this activation augments IL-6 mRNA expression and consecutively IL-6 release [18]. According to Witthaut and colleagues [10], who found a correlation between levels of natriuretic peptides and interleukin-6 plasma levels, the upregulation of IL-6 may effect cardiac release of natriuretic peptides. Thus, plasma levels of natriuretic peptides are not only affected by LV function, but also by secretion of inflammatory cytokines such as IL-6 in ICU shock patients. However, future studies evaluating the precise mechanisms responsible for enhanced natriuretic peptide secretion in critically ill patients are still needed.

In critically ill patients, the use of PAC neither increases overall mortality or days in hospital nor confers benefit. Despite almost 20 years of randomized clinical trials, a clear benefit leading to improved survival from the use of PAC has not been proven. The neutrality of PAC for clinical outcomes may result from the absence of effective evidence-based treatment regimens according to PAC information across the spectrum of critically ill patients. Further clinical trials should lead to the establishment of treatment protocols for the use of PAC in this patient population. The additional measurement of NT-proBNP in critically ill patients may provide promising decision support for the application of PAC and may help to identify candidates who might benefit from PAC measurements or be harmed by PAC.

Competing interests

The authors declare that they have no competing interests.

Acknowledgements

This work was supported by a grant of the Faculty of Clinical Medicine Mannheim, University of Heidelberg, Germany.

References

1. Jannuzzi JL, Morris A, Tung R, Pino R, Fifer MA, Thompson BT, Lewandrowski K: Natriuretic peptide testing for the evaluation of critically ill patients with shock in the intensive care unit: a prospective cohort study. Crit Care 2006, 10:R37.

2. Maisel SA, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Davis P, Ornato JP, Storrow AB, Abraham WT, Wu AH, et al.: Breathing not properly: multivariate study investigators: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.

3. Le Nem J, McGuire D, Drazner M: B-type natriuretic peptide in cardiovascular disease. Lancet 2003, 362:316-322.

4. Kazanegra R, Cheng V, Garcia A, Krishnaswamy P, Garretto N, Clopton P, Maisel A: A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail 2001, 7:21-29.

5. Sandham JD, Hull RD, Brant RF, Knox L, Pino GF, Doig CJ, Laporta DP, Viner S, Passerini L, Devitt H, et al.: Canadian critical care clinical trials group: A randomized controlled trial of the use of pulmonary catheters in high-risk surgical patients. N Engl J Med 2003, 348:5-14.

6. Connors AF Jr, Speroff T, Dawson NV, Thomas C, Harrell FE Jr, Wagner D, Desbiens N, Goldman L, Wu AW, Califf RM, et al.: The effectiveness of right heart catheterization in the initial care of critically ill patients. J Am Med Assoc 1996, 276:889-897.

7. Bone RC: Toward an epidemiology and natural history of SIRS (systemic inflammatory response syndrome). J Am Med Assoc 1992, 268:3452-3455.

8. Brueckmann M, Huhle G, Lang S, Haase KK, Bertsch Th, Weiß Ch, Kaden JJ, Putensen Ch, Borggreve M, Hoffmann U: Prognostic value of plasma N-terminal pro-brain natriuretic peptide in patients with severe sepsis. Circulation 2005, 112:527-534.

9. Chua G and Kang-Hoe: Marked elevations in N-terminal brain natriuretic peptide levels in septic shock. Crit Care 2004, 8:R248-R250.

10. Witthaut R, Busch Ch, Fraunberger P, Walli A, Seidel D, Plitz G, Stuttman R, Speichermann N, Verner L, Werdan K. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003, 29:1696-1702.

11. Roch A, Allardet-Servent J, Micheleot P, Oddoze Ch, Forel JM, Biaau K, Loundou A, Perrin G, Auffray JP, Portugal H, NH2-terminal pro-brain natriuretic peptide plasma level as an early marker of prognosis and cardiac dysfunction in septic shock patients. Crit Care Med 2005, 33:1001-1007.

12. Charpentier J, Luyt CE, Fella Y, Vinsonneau Ch, Caniou A, Grabar S, Oubront JF, Mira JP, Chiche JD: Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004, 32:660-665.

13. Tung RH, Garcia Ch, Morsos AM, Pino RM, Fifer MA, Thompson BT, Lewandrowski K, Lee-Lewandrowski E, Januzzi JL: Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004, 32:1643-1647.

14. Forfia PR, Watkins SP, Rame E, Stewart KJ, Shapiro EP: Relationship between B-type natriuretic peptides and pulmonary capillary wedge pressure in the intensive care unit. J Am Coll Cardiol 2005, 45:1887-1891.

15. Tomaru Ki K, Arai M, Yokoyama T, Aihara Y, Sekiguchi Ki K, Tanaka T, Nagai R, Kurabayashi M: Transcriptional activation of the BNP gene by lipopolysaccharide is mediated through GATA elements in neonatal rat cardiac myocytes. J Mol Cell Cardiol 2002, 34:649-659.

16. He Q, LaPonte MC: Interleukin-1β regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999, 33:283-289.

17. Kuwahara K, Saito Y, Harada M, Ishikawa M, Ogawa E, Miyamoto Y, Hamanaka I, Kamitani S, Kajiyama N, Takahashi N, et al.: Involvement of cardiotrophin-1 in cardiac myocyte-nonmyocyte interactions during hypertrophy of rat cardiac myocytes in vitro. Circulation 1999, 100:1116-1124.

18. Pan J, Fukuda K, Saito M, Matsuzaki J, Kodama H, Sano M, Takahashi T, Kato T, Ogawa S: Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 1998, 84:1127-1136.